Divi’s Laboratories Faces ₹570 Crore Tax Demand

What Is the Tax Issue? 

The Income Tax Department issued a draft assessment order under Section 144C(1)on March 20, 2026 which the company received on March 21. The order proposes additions of ₹570.51 crore to the company’s income for FY 2022–23. 

Main reasons: 

•Transfer pricing adjustments in domestic transactions 

•Certain corporate tax disallowances 
 

The department has also indicated that penalty proceedings under Section 270Amay be initiated. This is not a final tax demand. It is only a draft order.Divi’s has 30 daysto file objections before the Dispute Resolution Panel (DRP). A final decision will come only after this process. 

Why Do Transfer Pricing Disputes Occur? 

Transfer pricing issues are common for companies with multiple units or related-party transactions. 

In simple terms: 

•When one unit sells goods to another, prices must match market rates (“arm’s length”). 
•Pharma companies often transfer materials between plants, making pricing complex. 
•Tax authorities and companies may have different views on valuation. 

Such disputes are common in the pharma sector and are usually resolved through appeals. 

Divi’s Official Response 

The company stated: 

“The company is evaluating the Draft Order and intends to file an appeal within the stipulated time.” 

This is a standard response and indicates confidence. 

•No immediate cash outflow 
•No impact on business operations 
•No change in FY26 outlook 
 

Will This Impact the Stock? 

So far the market reaction has been limited. 

Reasons for stability: 

•Strong cash reserves 

•Consistent business growth 
•History of handling tax disputes successfully 

Even if part of the tax demand becomes payable in the future, impact is likely to be manageable given the company’s large size and profitability. 

What This Means for the Pharma Sector 

This case highlights three major trends: 

1.Increased scrutiny on transfer pricing 

2.Focus on domestic transactions 

3.Short-term opportunities during uncertainty 

Temporary corrections in quality stocks can create good entry points for long-term investors. 
 

What Should Investors Do? 

There is no need to panic. 

Suggested approach: 

•Review your portfolio allocation 

•Track upcoming quarterly results 

•Watch for updates on the DRP decision 

•Diversify within the pharma sector if needed 

For long-term investors this does not change the company’s core story. 

Final Thoughts: Opportunity or Concern? 

Divi’s Laboratories remains a strong company with: 

•A solid business model 

•Global presence 

•Strong financials 

A draft tax order may create short term noise but it does not change the long term growth story. 
 

Disclaimer 

This article is for educational purposes only and does not constitute investment advice. Please consult a financial advisor before making investment decisions. All information is based on publicly available data as of March 24, 2026.